What is Bone Biologics Corp's earnings per share (EPS)?

Bone Biologics Corp (BBLG) reported diluted earnings per share of $-2.65 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Bone Biologics Corp Financials

BBLG

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Bone Biologics Corp (BBLG) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 20 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BBLG FY2025 2026-05-14

Bone Biologics is operating as a cash-funded development company, with equity financing repeatedly covering losses while R&D intensity resets lower.

The clearest shift is that cash burn eased from -$9.56M in FY2023 to -$2.69M in FY2025, but that improvement came mainly from R&D falling from $6.91M to $1.06M while SG&A stayed near $2.1M-$2.5M. That points less to operating leverage and more to management dialing development activity up or down to preserve cash between raises.

FY2025 ended with $5.33M of cash against just $419K of liabilities and no long-term debt shown, so near-term balance-sheet pressure is low even though operations remain loss-making. The current ratio of 13.8x suggests the asset base is still mostly liquidity rather than productive operating assets.

Across FY2023-FY2025, financing inflows totaled about $14.2M while operating cash outflow totaled about -$16.4M, showing outside capital has been the company’s main funding source. The retained deficit of -$88.1M means losses are cumulative, so the business has been sustained by repeated recapitalization rather than by cash generated from commercial activity.

Financial Health Signals

Financial Profile 33/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Bone Biologics Corp's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

100

Bone Biologics Corp carries a low D/E ratio of 0.08, meaning only $0.08 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 13.85, Bone Biologics Corp holds $13.85 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Returns

Bone Biologics Corp generates a -57.8% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -118.1% the prior year.

Piotroski F-Score Weak

3/9

Bone Biologics Corp passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.87x

For every $1 of reported earnings, Bone Biologics Corp generates $0.87 in operating cash flow (-$2.7M OCF vs -$3.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$3.1M

YoY+24.4%

Bone Biologics Corp reported -$3.1M in net income in fiscal year 2025. This represents an increase of 24.4% from the prior year.

EPS (Diluted)

$-2.65

Bone Biologics Corp earned $-2.65 per diluted share (EPS) in fiscal year 2025. This represents an increase of 90.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$5.3M

YoY+60.4%

5Y CAGR+365.8%

10Y CAGR+7.2%

Bone Biologics Corp held $5.3M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

Bone Biologics Corp had 2M shares outstanding in fiscal year 2025. This represents an increase of 264.6% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-57.8%

YoY+60.2pp

Bone Biologics Corp's ROE was -57.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 60.2 percentage points from the prior year.

Capital Allocation

R&D Spending

$1.1M

YoY-50.2%

5Y CAGR+25.5%

10Y CAGR+5.5%

Bone Biologics Corp invested $1.1M in research and development in fiscal year 2025. This represents a decrease of 50.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

BBLG Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	$1.1B
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$1.1M-50.2%	$2.1M-69.2%	$6.9M+337.4%	$1.6M+1824.9%	$82K-75.9%	$341K
SG&A Expenses	$2.2M+4.1%	$2.1M-17.1%	$2.5M+20.8%	$2.1M+104.3%	$1.0M+110.8%	$484K
Operating Income	-$3.2M+23.3%	-$4.2M+55.3%	-$9.4M-157.2%	-$3.7M-232.3%	-$1.1M-33.7%	-$825K
Interest Expense	N/A	N/A	$2K	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	$2K0.0%	$2K
Net Income	-$3.1M+24.4%	-$4.1M+54.0%	-$8.9M-502.8%	-$1.5M+7.8%	-$1.6M+11.7%	-$1.8M
EPS (Diluted)	$-2.65	$-28.96+14.8%	$-34.01	$-31.15	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$142K	N/A	$188K-2.0%	$192K-54.8%	$424K	N/A	$430K+22.6%	$350K
SG&A Expenses	$663K	N/A	$527K-5.2%	$556K-9.5%	$615K	N/A	$521K+13.5%	$459K
Operating Income	-$805K	N/A	-$715K+4.4%	-$748K+28.0%	-$1.0M	N/A	-$951K-17.5%	-$810K
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$766K	N/A	-$667K+10.0%	-$741K+27.2%	-$1.0M	N/A	-$941K-20.1%	-$784K
EPS (Diluted)	$-0.43	N/A	$-0.37+72.2%	$-1.33+30.7%	$-1.92	N/A	$-14.21-253.5%	$-4.02

BBLG Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$5.8M+50.1%	$3.9M+3.3%	$3.7M-56.0%	$8.5M+27.3%	$6.7M	$0
Current Assets	$5.8M+50.1%	$3.9M+3.3%	$3.7M-56.0%	$8.5M	N/A	N/A
Cash & Equivalents	$5.3M+60.4%	$3.3M+9.9%	$3.0M-59.9%	$7.5M+12.9%	$6.7M+274380.5%	$2K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$419K+10.8%	$378K-54.6%	$831K-67.4%	$2.5M+2450.2%	$100K-99.3%	$13.7M
Current Liabilities	$419K+10.8%	$378K-54.6%	$831K-67.4%	$2.5M+2450.2%	$100K-99.3%	$13.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$5.4M+54.4%	$3.5M+19.9%	$2.9M-51.1%	$5.9M-9.6%	$6.6M+148.0%	-$13.7M
Retained Earnings	-$88.1M-3.7%	-$85.0M-5.1%	-$80.9M-12.4%	-$72.0M-2.1%	-$70.5M-2.3%	-$68.9M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$5.0M-14.1%	$5.8M-8.7%	$6.4M-9.3%	$7.0M+121.4%	$3.2M-18.1%	$3.9M-5.0%	$4.1M+27.3%	$3.2M
Current Assets	$5.0M-14.1%	$5.8M-8.7%	$6.4M-9.3%	$7.0M+121.4%	$3.2M-18.1%	$3.9M-5.0%	$4.1M+27.3%	$3.2M
Cash & Equivalents	$4.5M-15.1%	$5.3M-11.8%	$6.0M-8.9%	$6.6M+141.8%	$2.7M-17.4%	$3.3M-6.8%	$3.6M+52.9%	$2.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$309K-26.1%	$419K+25.2%	$334K-17.7%	$406K+61.7%	$251K-33.5%	$378K+38.2%	$273K-3.9%	$285K
Current Liabilities	$309K-26.1%	$419K+25.2%	$334K-17.7%	$406K+61.7%	$251K-33.5%	$378K+38.2%	$273K-3.9%	$285K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$4.7M-13.2%	$5.4M-10.6%	$6.0M-8.8%	$6.6M+126.6%	$2.9M-16.4%	$3.5M-8.1%	$3.8M+30.4%	$2.9M
Retained Earnings	-$88.9M-0.9%	-$88.1M-0.8%	-$87.4M-0.8%	-$86.8M-0.9%	-$86.0M-1.2%	-$85.0M-1.8%	-$83.5M-1.1%	-$82.6M

BBLG Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$2.7M+34.8%	-$4.1M+56.8%	-$9.6M-167.9%	-$3.6M-190.3%	-$1.2M-187.8%	-$427K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$4.7M+6.3%	$4.4M-12.3%	$5.0M+13.9%	$4.4M-44.0%	$7.9M+1862.3%	$403K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$804K-12.5%	-$715K-20.9%	-$591K-28.9%	-$459K+50.5%	-$926K+31.6%	-$1.4M-136.6%	-$572K+36.1%	-$896K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$348K	$0	$0-100.0%	$4.4M+1152.4%	$348K-68.8%	$1.1M-38.4%	$1.8M+604087.3%	$299
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BBLG Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	-0.1%
Net Margin	N/A	N/A	N/A	N/A	N/A	-0.2%
Return on Equity	-57.8%+60.2pp	-118.1%+189.8pp	-307.9%-282.9pp	-25.0%-0.5pp	-24.5%	N/A
Return on Assets	-53.6%+52.9pp	-106.5%+132.9pp	-239.4%-221.9pp	-17.5%+6.6pp	-24.1%	N/A
Current Ratio	13.85+3.6	10.22+5.7	4.50+1.2	3.33	N/A	N/A
Debt-to-Equity	0.08-0.0	0.11-0.2	0.29-0.1	0.43+0.4	0.02+1.0	-1.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-16.4%	N/A	-11.1%+0.2pp	-11.2%+23.7pp	-34.9%	N/A	-24.8%+2.1pp	-26.9%
Return on Assets	-15.4%	N/A	-10.5%+0.1pp	-10.6%+21.6pp	-32.2%	N/A	-23.1%+1.4pp	-24.5%
Current Ratio	16.09+2.2	13.85-5.2	19.00+1.8	17.24+4.7	12.59+2.4	10.22-4.6	14.87+3.6	11.22
Debt-to-Equity	0.07-0.0	0.08+0.0	0.060.0	0.06-0.0	0.09-0.0	0.11+0.0	0.07-0.0	0.10
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Nuwellis Inc NUWE

$2.7M

Catheter Precision VTAK

$2.1M

Venus Concept Inc VERO

$2.1M

Nanovibronix Inc NAOV

$4.4M

Tivic Health Systems Inc TIVC

$4.0M

Frequently Asked Questions

Is Bone Biologics Corp profitable?

No, Bone Biologics Corp (BBLG) reported a net income of -$3.1M in fiscal year 2025.

What is Bone Biologics Corp's return on equity (ROE)?

Bone Biologics Corp (BBLG) has a return on equity of -57.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Bone Biologics Corp's operating cash flow?

Bone Biologics Corp (BBLG) generated -$2.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Bone Biologics Corp's total assets?

Bone Biologics Corp (BBLG) had $5.8M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Bone Biologics Corp spend on research and development?

Bone Biologics Corp (BBLG) invested $1.1M in research and development during fiscal year 2025.

How many shares does Bone Biologics Corp have outstanding?

Bone Biologics Corp (BBLG) had 2M shares outstanding as of fiscal year 2025.

What is Bone Biologics Corp's current ratio?

Bone Biologics Corp (BBLG) had a current ratio of 13.85 as of fiscal year 2025, which is generally considered healthy.

What is Bone Biologics Corp's debt-to-equity ratio?

Bone Biologics Corp (BBLG) had a debt-to-equity ratio of 0.08 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Bone Biologics Corp's return on assets (ROA)?

Bone Biologics Corp (BBLG) had a return on assets of -53.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Bone Biologics Corp's cash runway?

Based on fiscal year 2025 data, Bone Biologics Corp (BBLG) had $5.3M in cash against an annual operating cash burn of $2.7M. This gives an estimated cash runway of approximately 24 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Bone Biologics Corp's Piotroski F-Score?

Bone Biologics Corp (BBLG) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Bone Biologics Corp's earnings high quality?

Bone Biologics Corp (BBLG) has an earnings quality ratio of 0.87x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Bone Biologics Corp?

Bone Biologics Corp (BBLG) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.